Advances in immuno-positron emission tomography: Antibodies for molecular imaging in oncology

Journal of Clinical Oncology

Volumn 30, Issue 31, 2012, Pages 3884-3892

  Knowles, Scott M ^a   Wu, Anna M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICD44V6 U36 ZR 89; ARCITUMOMAB TC 99M; CAPROMAB PENDETIDE IN 111; CCG250 I 124; CD44V6 ANTIGEN; COPPER 64; DIABODY; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IBRITUMOMAB TIUXETAN; IODINE 124; IODOTYROSINE; MINIBODY; MONOCLONAL ANTIBODY B.72.3 IN 111; N SUCCINYLDESFERRIOXAMINE ZR 89; NOFETUMOMAB MERPENTAN TC 99M; ONCOSCINT; PENTETATE INDIUM IN 111; RADIOISOTOPE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB; TRASTUZUMAB N SUCCINYLDESFERRIOXAMINE ZR 89; TRASTUZUMAB PENTETATE INDIUM IN 111; TRASTUZUMAB ZR 89; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 86; ZIRCONIUM 89;

ANTIBODY ENGINEERING; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; CANCER THERAPY; CELL SURFACE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG HALF LIFE; DRUG UPTAKE; HUMAN; IMMUNOPOSITRON EMISSION TOMOGRAPHY; ISOTOPE LABELING; LYMPH NODE METASTASIS; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOLOGY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RADIOIMMUNOTHERAPY; REVIEW; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 84869114917     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.4887     Document Type: Review

References (119)

1. Pillay V, Gan HK, Scott AM: Antibodies in oncology. N Biotechnol 28:518-529, 2011
2. Steeg PS: Heterogeneity of drug target expression among metastatic lesions: Lessons from a breast cancer autopsy program. Clin Cancer Res 14:3643-3645, 2008
3. Czernin J, Allen-Auerbach M, Schelbert HR: Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 48:78S-88S, 2007 (suppl 1)
4. Gambhir SS, Czernin J, Schwimmer J, et al: A tabulated summary of the FDG PET literature. J Nucl Med 42:1S-93S, 2001 (suppl) (Pubitemid 32423895)
5. Zhu A, Lee D, Shim H: Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol 38:55-69, 2011
6. Shreve PD, Anzai Y, Wahl RL: Pitfalls in oncologic diagnosis with FDG PET imaging: Physiologic and benign variants. Radiographics 19:61-77, 1999; quiz 150-151
7. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 144:646-674, 2011
8. Hong H, Sun J, Cai W: Radionuclide-based cancer imaging targeting the carcinoembryonic antigen. Biomark Insights 3:435-451, 2008
9. Colcher D, Minelli MF, Roselli M, et al: Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res 48:4597-4603, 1988
10. Li L, Turatti F, Crow D, et al: Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET. J Nucl Med 51:1139-1146, 2010
11. Zou P, Povoski SP, Hall NC, et al: 124IHuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: Preliminary results. World J Surg Oncol 8:65, 2010
12. Sundaresan G, Yazaki PJ, Shively JE, et al: 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nucl Med 44:1962-1969, 2003 (Pubitemid 40022142)
13. Cai W, Olafsen T, Zhang X, et al: PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 48:304-310, 2007 (Pubitemid 47555358)
14. van Rij CM, Sharkey RM, Goldenberg DM, et al: Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. J Nucl Med 52:1601-1607, 2011
15. Olafsen T, Betting D, Kenanova VE, et al: Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50:1500-1508, 2009
16. Olafsen T, Sirk SJ, Betting DJ, et al: ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel 23:243-249, 2010
17. Holland JP, Divilov V, Bander NH, et al: 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med 51:1293-1300, 2010
18. Alt K, Wiehr S, Ehrlichmann W, et al: High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate 70:1413-1421, 2010
19. Elsässer-Beile U, Reischl G, Wiehr S, et al: PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 50:606-611, 2009
20. Olafsen T, Ho DT, Lipman AA, et al: Highly-specific small animal PET imaging of prostate specific membrane antigen (PSMA) xenografts by an engineered humanized antibody fragment (minibody). Presented at the World Molecular Imaging Conference, Kyoto, Japan, September 8-11, 2010
21. Olafsen T, Gu Z, Sherman MA, et al: Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 30:396-405, 2007 (Pubitemid 46684429)
22. Leyton JV, Olafsen T, Lepin EJ, et al: Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res 14:7488-7496, 2008
23. Leyton JV, Olafsen T, Sherman MA, et al: Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel 22:209-216, 2009
24. Lepin EJ, Leyton JV, Zhou Y, et al: An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging 37:1529-1538, 2010
25. Liu K, Lepin EJ, Wang MW, et al: Microfluidic-based 18F-labeling of biomolecules for immuno-positron emission tomography. Mol Imaging 10:168-176, 1-7, 2011
26. Olafsen T, Tan GJ, Cheung CW, et al: Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17:315-323, 2004 (Pubitemid 39093511)
27. Robinson MK, Doss M, Shaller C, et al: Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65:1471-1478, 2005 (Pubitemid 40270176)
28. Olafsen T, Kenanova VE, Sundaresan G, et al: Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Res 65:5907-5916, 2005 (Pubitemid 40911197)
29. Dijkers EC, Oude Munnink TH, Kosterink JG, et al: Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 87: 586-592, 2010
30. Wong JY, Raubitschek A, Yamauchi D, et al: A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother Radiopharm 25:387-394, 2010
31. Holland JP, Caldas-Lopes E, Divilov V, et al: Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 5:e8859, 2010
32. Oude Munnink TH, Korte MA, Nagengast WB, et al: (89)Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVPAUY922 in a human tumour xenograft. Eur J Cancer 46:678-684, 2010
33. Reddy S, Shaller CC, Doss M, et al: Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment. Clin Cancer Res 17:1509-1520, 2011
34. Olafsen T, Sirk SJ, Olma S, et al: ImmunoPET using engineered antibody fragments: Fluorine-18 labeled diabodies for same-day imaging. Tumour Biol 33:669-677, 2012
35. Heskamp S, van Laarhoven HW, Molkenboer- Kuenen JD, et al: ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med 51:1565-1572, 2010
36. Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, et al: Predicting IGF-1R therapy response in bone sarcomas: Immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 17:7693-7703, 2011
37. Nayak TK, Regino CA, Wong KJ, et al: PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab. Eur J Nucl Med Mol Imaging 37:1368-1376, 2010
38. Nayak TK, Garmestani K, Milenic DE, et al: HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts. PLoS One 6:e18198, 2011
39. Yoshida C, Tsuji AB, Sudo H, et al: Development of positron emission tomography probe of 64Cu-labeled anti-C-kit 12A8 Fab to measure protooncogene C-kit expression. Nucl Med Biol 38:331-337, 2011
40. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, et al: PET with the 89Zr-labeled transforming growth factor-beta antibody fresolimumab in tumor models. J Nucl Med 52:2001-2008, 2011
41. Eder M, Knackmuss S, Le Gall F, et al: 68Ga-labelled recombinant antibody variants for immuno-PET imaging of solid tumours. Eur J Nucl Med Mol Imaging 37:1397-1407, 2010
42. McCabe KE, Liu B, Marks JD, et al: An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol 14:336-347, 2012
43. Pfaffen S, Frey K, Stutz I, et al: Tumourtargeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nucl Med Mol Imaging 37:1559-1565, 2010
44. Girgis MD, Kenanova V, Olafsen T, et al: Anti-CA19-9 diabody as a PET imaging probe for pancreas cancer. J Surg Res 170:169-178, 2011
45. Kelly MP, Lee FT, Tahtis K, et al: Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm 23:411-423, 2008
46. Lövqvist A, Humm J, Sheikh A: PET imaging of (86) Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: Comparison between (86) Y and (111) In radiolabels. J Nucl Med 42:1281-1287, 2001 (Pubitemid 32717850)
47. Carlin S, Khan N, Ku T, et al: Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One 5:e10857, 2010
48. Divgi CR, Pandit-Taskar N, Jungbluth AA, et al: Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: A phase I trial. Lancet Oncol 8:304-310, 2007 (Pubitemid 46464522)
49. Pryma DA, O'Donoghue JA, Humm JL, et al: Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J Nucl Med 52:535-540, 2011
50. Nagengast WB, de Korte MA, Oude Munnink TH, et al: 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 51:761-767, 2010
51. Nagengast WB, de Vries EG, Hospers GA, et al: In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48:1313-1319, 2007 (Pubitemid 47242797)
52. 111In-bevacizumab in stage III/IV melanoma patients. Eur J Cancer 47:1595-1602, 2011
53. Tijink BM, Perk LR, Budde M, et al: (124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging 36:1235-1244, 2009
54. Rossin R, Berndorff D, Friebe M, et al: Small-animal PET of tumor angiogenesis using a (76)Brlabeled human recombinant antibody fragment to the ED-B domain of fibronectin. J Nucl Med 48:1172-1179, 2007 (Pubitemid 47052658)
55. Hong H, Severin GW, Yang Y, et al: Positron emission tomography imaging of CD105 expression with (89)Zr-Df-TRC105. Eur J Nucl Med Mol Imaging 39:138-148, 2012
56. Hong H, Yang Y, Zhang Y, et al: Positron emission tomography imaging of CD105 expression during tumor angiogenesis. Eur J Nucl Med Mol Imaging 38:1335-1343, 2011
57. Mumprecht V, Honer M, Vigl B, et al: In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res 70:8842-8851, 2010
58. Zhiqiang A: Therapeutic Monoclonal Antibodies: From Bench to Clinic (ed 1). Hoboken, NJ, John Wiley & Sons, 2009
59. Rahmim A, Zaidi H: PET versus SPECT: Strengths, limitations and challenges. Nucl Med Commun 29:193-207, 2008 (Pubitemid 351499295)
60. Nayak TK, Brechbiel MW: Radioimmunoimaging with longer-lived positron-emitting radionuclides: Potentials and challenges. Bioconjug Chem 20:825-841, 2009
61. Tolmachev V, Stone-Elander S: Radiolabelled proteins for positron emission tomography: Pros and cons of labelling methods. Biochim Biophys Acta 1800:487-510, 2010
62. Boswell CA, Brechbiel MW: Development of radioimmunotherapeutic and diagnostic antibodies: An inside-out view. Nucl Med Biol 34:757-778, 2007 (Pubitemid 47503817)
63. Verel I, Visser GW, Boellaard R, et al: Zr-89 immuno-PET: Comprehensive procedures for the production of Zr-89-labeled monoclonal antibodies. J Nucl Med 44:1271-1281, 2003 (Pubitemid 39662684)
64. Pentlow KS, Finn RD, Larson SM, et al: Quantitative imaging of yttrium-86 with PET: The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging 3:85-90, 2000
65. Pentlow KS, Graham MC, Lambrecht RM, et al: Quantitative imaging of iodine-124 with PET. J Nucl Med 37:1557-1562, 1996 (Pubitemid 26321647)
66. Stein R, Govindan SV, Mattes MJ, et al: Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 63:111-118, 2003 (Pubitemid 36070428)
67. Stein R, Goldenberg DM, Thorpe SR, et al: Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors. Cancer Res 55:3132-3139, 1995
68. Tinianow JN, Gill HS, Ogasawara A: Sitespecifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol 37:289-297, 2010
69. Lewis MR, Shively JE: Maleimidocysteineamido-DOTA derivatives: New reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. Bioconjug Chem 9:72-86, 1998 (Pubitemid 28052088)
70. Khawli LA, van den Abbeele AD, Kassis AI: N-(m-[125I]iodophenyl) maleimide: An agent for high yield radiolabeling of antibodies. Int J Rad Appl Instrum B 19:289-295, 1992
71. Sharkey RM, Chang CH, Rossi EA, et al: Pretargeting: Taking an alternate route for localizing radionuclides. Tumour Biol 33:591-600, 2012
72. Wu AM, Olafsen T: Antibodies for molecular imaging of cancer. Cancer J 14:191-197, 2008
73. Börjesson PK, Jauw YW, Boellaard R, et al: Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res 12:2133-2140, 2006
74. Perik PJ, Lub-De Hooge MN, Gietema JA, et al: Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 24:2276-2282, 2006 (Pubitemid 46630657)
75. Dijkers EC, Kosterink JG, Rademaker AP, et al: Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med 50:974-981, 2009
76. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, et al: (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med 52:1173-1180, 2011
77. O'Donoghue JA, Smith-Jones PM, Humm JL, et al: 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET. J Nucl Med 52:1878-1885, 2011
78. Al-Ahmadie HA, Alden D, Qin LX, et al: Carbonic anhydrase IX expression in clear cell renal cell carcinoma: An immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 32:377-382, 2008 (Pubitemid 351398928)
79. Uzzo RG, Russo PN, Chen D, et al: Multicenter phase III REDECT trial with 124I-girentuximab positron emission tomography/computed tomography for the presurgical detection of clear cell renal cell carcinoma. Presented at the Annual Meeting of the American Urological Association-Northeastern Section, New Orleans, LA, October 26-30, 2011
80. Stillebroer A, Franssen G, Oyen W, et al: ImmunoPET imaging of renal cell carcinoma with 124I- and 89Zr-labeled anti-CAIX monoclonal antibody cG250. Presented at the Annual Meeting of the Society of Nuclear Medicine, Salt Lake City, UT, June 5-9, 2010
81. Vogel CA, Bischof-Delaloye A, Mach JP, et al: Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab′)2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer 68:684-690, 1993 (Pubitemid 23301269)
82. Buchegger F, Haskell CM, Schreyer M, et al: Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human-colon carcinoma grafted into nude mice. J Exp Med 158:413-427, 1983 (Pubitemid 13049397)
83. Slavin-Chiorini DC, Kashmiri SV, Lee HS, et al: A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 12:305-316, 1997 (Pubitemid 28009374)
84. Shu L, Qi CF, Schlom J, et al: Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci U S A 90:7995-7999, 1993 (Pubitemid 23260841)
85. Roopenian DC, Akilesh S: FcRn: The neonatal Fc receptor comes of age. Nat Rev Immunol 7:715-725, 2007 (Pubitemid 47327396)
86. Slavin-Chiorini DC, Kashmiri SV, Schlom J, et al: Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res 55:5957s-5967s, 1995
87. Kenanova V, Olafsen T, Crow DM, et al: Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res 65:622-631, 2005
88. Olafsen T, Kenanova VE, Wu AM: Tunable pharmacokinetics: Modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 1:2048-2060, 2006 (Pubitemid 46773329)
89. Mueller BM, Reisfeld RA, Gillies SD: Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc Natl Acad Sci U S A 87:5702-5705, 1990
90. Hu S, Shively L, Raubitschek A, et al: Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 56:3055-3061, 1996
91. Milenic DE, Yokota T, Filpula DR, et al: Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res 51:6363-6371, 1991
92. Adams GP, Tai MS, McCartney JE, et al: Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 12:1599-1605, 2006
93. Olafsen T, Cheung CW, Yazaki PJ, et al: Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel 17:21-27, 2004 (Pubitemid 38173165)
94. Berry DJ, Ma Y, Ballinger JR, et al: Efficient bifunctional gallium-68 chelators for positron emission tomography: Tris(hydroxypyridinone) ligands. Chem Commun (Camb) 47:7068-7070, 2011
95. Kiesewetter DO, Jacobson O, Lang L, et al: Automated radiochemical synthesis of [18F]FBEM: A thiol reactive synthon for radiofluorination of peptides and proteins. Appl Radiat Isot 69:410-414, 2011
96. Cho EY, Han JJ, Choi YL, et al: Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: An immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci 23:1053-1061, 2008
97. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002 (Pubitemid 34111379)
98. Valero V, Forbes J, Pegram MD, et al: Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2 gene-amplified metastatic breast cancer (BCIRG 007 study): Two highly active therapeutic regimens. J Clin Oncol 29:149-156, 2011
99. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
100. Perez EA, Suman VJ, Rowland KM, et al: Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6:425-432, 2005 (Pubitemid 43078898)
101. Behr TM, Béhé M, Wörmann B: Trastuzumab and breast cancer. N Engl J Med 345:995- 996, 2001
102. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000 (Pubitemid 30159851)
103. Dewaraja YK, Schipper MJ, Roberson PL, et al: 131I-tositumomab radioimmunotherapy: Initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 51:1155-1162, 2010
104. Larson SM, Pentlow KS, Volkow ND, et al: PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 33:2020-2023, 1992
105. Walrand S, Flux GD, Konijnenberg MW, et al: Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging? Eur J Nucl Med Mol Imaging 38:S57-S68, 2011 (suppl 1)
106. Perk LR, Visser OJ, Stigter-van Walsum M, et al: Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 33:1337-1345, 2006 (Pubitemid 44630790)
107. Kenanova V, Olafsen T, Williams LE, et al: Radioiodinated versus radiometal-labeled anticarcinoembryonic antigen single-chain Fv-Fc antibody fragments: Optimal pharmacokinetics for therapy. Cancer Res 67:718-726, 2007 (Pubitemid 46192212)
108. Czabanka M, Parmaksiz G, Bayerl SH, et al: Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. Eur J Cancer 47:1276-1284, 2011
109. El-Emir E, Dearling JL, Huhalov A, et al: Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer 96:1862-1870, 2007 (Pubitemid 46912019)
110. Tijink BM, Neri D, Leemans CR, et al: Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47:1127-1135, 2006 (Pubitemid 47544908)
111. Berndorff D, Borkowski S, Sieger S, et al: Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: Identification of the best-suited radioimmunoconjugate. Clin Cancer Res 11:7053s-7063s, 2005 (Pubitemid 41428704)
112. Borsi L, Balza E, Bestagno M, et al: Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102:75-85, 2002
113. Smith-Jones PM, Solit DB, Akhurst T, et al: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701-706, 2004 (Pubitemid 38702826)
114. Nagengast WB, Lub-de Hooge MN, Oosting SF, et al: VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 71:143-153, 2011
115. Wright GL Jr, Grob BM, Haley C, et al: Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326-334, 1996 (Pubitemid 26279634)
116. Evans MJ, Smith-Jones PM, Wongvipat J, et al: Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 108:9578-9582, 2011
117. Ruggiero A, Holland JP, Hudolin T, et al: Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med 52:1608-1615, 2011
118. Shah C, Miller TW, Wyatt SK, et al: Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res 15:4712-4721, 2009
119. Kohanim S, Yang D, Kurzrock R, et al: Assessment of cell apoptosis using radiolabeled ECTRAIL antibody. Presented at the Annual Meeting of the Society of Nuclear Medicine, Washington, DC, June 2-6, 2007